|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancer immunotherapy .net |
|
|
|
Information on human tumours 3 |
|
|
|
|
|
|
|
cancerimmunotherapy@yahoo.com |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
tumour type |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nasopharyngeal carcinoma |
|
|
|
|
|
|
|
|
|
Data in brief:
Five-year disease-free survival: 8% without local IL-2 (radiation only) 63% with local IL-2
Phase III study is planned
See also press release Zie ook persbericht |
|
|
|
2005 |
|
|
|
|
|
|
|
Jacobs et al. (2005) Cancer Immunology, Immunotherapy 54, 792-8 |
|
|
|
This research will be highlighted in the october 2005 edition of nature clinical practices oncology |
|
|
|
|
|
|
|
tumour type |
|
|
|
|
|
|
|
|
|
|
|
Interleukin-2 (IL-2) Mechanism of IL-2 therapy of cancer Cancers sensitve to IL-2 Surgery and IL-2 Radiotherapy and IL-2 Chemotherapy and IL-2 Experts I want to co-operate (doctors) Frequently Asked Questions (FAQs) |
|
|
|
|
|
|
|
|
|
Information for doctors
Information for patients
I want to support this research or more information on the EPTI fund supporting this research |
|
|
|
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands |
|
|
|
|
|
|
|